GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases.
Boston Pharmaceuticals will focus on developing drugs that are already clinic-ready - outsourcing much of the clinical work to CROs and bringing novel drugs to late stage trials or commercialization.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.